marketcap
Facebook
Twitter
Telegram
Report an ErrorAnnual report 2023
added 04-08-2024
Eiger BioPharmaceuticals Balance Sheet 2011-2024 | EIGR
Annual Balance Sheet Eiger BioPharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
10.2 M | 4.33 M | 46.6 M | 3.45 M | -16.9 M | 19.2 M | -27.3 M | -4.33 M | -6.86 M | -13.8 M | - | ||
Long Term Debt |
- | 39.6 M | 31.8 M | 31.2 M | 30.4 M | 25.6 M | 13.1 M | 14.7 M | - | 10.1 M | - | - | - |
Long Term Debt Current |
84 K | 491 K | 628 K | 582 K | 534 K | - | 2 M | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 31.9 M | 31.7 M | 25.8 M | 13.1 M | 14.7 M | 24 K | 10.4 M | 5.49 M | 10.3 M | - |
Total Current Liabilities |
53.3 M | 25.1 M | 29.9 M | 16.6 M | 16.9 M | 10 M | 7.27 M | 5.29 M | 8.39 M | 6.61 M | - | - | - |
Total Liabilities |
53.3 M | 64.8 M | 54 M | 48.6 M | 48.7 M | 35.9 M | 20.4 M | 20 M | 2.33 M | 17 M | 12 M | 12.1 M | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-512 M | -437 M | -340 M | -306 M | -241 M | -171 M | -119 M | -76.4 M | -191 M | -146 M | -113 M | -92.6 M | - |
Total Assets |
38.8 M | 120 M | 126 M | 144 M | 105 M | 102 M | 42.9 M | 60.7 M | 33.9 M | 89.1 M | 21.2 M | 35.9 M | - |
Cash and Cash Equivalents |
25.4 M | 25.8 M | 22.2 M | 28.9 M | 39.4 M | 61.3 M | 32 M | 27.8 M | 4.78 M | 777 K | 145 K | 13.8 M | - |
Book Value |
-14.5 M | 55.3 M | 72.4 M | 95 M | 56.5 M | 66.6 M | 22.5 M | 40.7 M | 31.6 M | 72.1 M | 9.11 M | 23.9 M | - |
Total Shareholders Equity |
-14.5 M | 55.3 M | 72.4 M | 95 M | 56.5 M | 66.6 M | 22.5 M | 40.7 M | -5.15 M | 531 K | 105 K | -28.4 M | - |
All numbers in USD currency
Quarterly Balance Sheet Eiger BioPharmaceuticals
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
40.7 M | 40.3 M | 40 M | 39.6 M | 39.3 M | - | 19.4 M | 24 M | 28.5 M | 31.4 M | 31.2 M | 31.2 M | 31.2 M | 31.2 M | 31.2 M | 30.4 M | 30.4 M | 30.4 M | 30.4 M | 25.6 M | 25.6 M | 25.6 M | 25.6 M | 13.1 M | 13.1 M | 13.1 M | 13.1 M | 14.7 M | - | 14.7 M | 14.7 M | - | - | 10 K | 8.71 M | 11.8 M | 9.91 M | 10.1 M | 10.1 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 29 K | 283 K | - | 298 K | 111 K | 298 K | - | 37 K | 37 K | 37 K | - | - | - | - | - | - | - | - | - |
Total Liabilities |
57.3 M | 57.1 M | 64 M | 64.8 M | 65.4 M | - | 56.1 M | 54 M | 50.8 M | 47.7 M | 49.3 M | 48.6 M | 48.6 M | 48.6 M | 48.6 M | 48.7 M | 48.7 M | 48.7 M | 48.7 M | 35.9 M | 35.9 M | 35.9 M | 35.9 M | 20.4 M | 20.4 M | 20.4 M | 20.4 M | 20 M | 20 M | 20 M | 20 M | 10.7 M | 10.7 M | 10.7 M | 10.7 M | 286 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-499 M | -481 M | -460 M | -437 M | -412 M | - | -363 M | -340 M | -319 M | -296 M | -277 M | -306 M | -306 M | -306 M | -306 M | -241 M | -241 M | -241 M | -241 M | -171 M | -171 M | -171 M | -171 M | -119 M | -119 M | -119 M | -119 M | -76.4 M | -76.4 M | -76.4 M | -76.4 M | -29.3 M | -29.3 M | -29.3 M | -29.3 M | -15.9 M | -146 M | -146 M | -146 M | -113 M | -113 M | - | - | - | - | - | - | - | - | - | - |
Total Assets |
55.7 M | 72.4 M | 99.2 M | 120 M | 144 M | - | 153 M | 126 M | 140 M | 157 M | 176 M | 144 M | 144 M | 144 M | 144 M | 105 M | 105 M | 105 M | 105 M | 102 M | 102 M | 102 M | 102 M | 42.9 M | 42.9 M | 42.9 M | 42.9 M | 60.7 M | 60.7 M | 60.7 M | 60.7 M | 5.58 M | 5.58 M | 5.58 M | 5.58 M | 816 K | 89.1 M | 89.1 M | 89.1 M | 21.2 M | 21.2 M | 21.2 M | 21.2 M | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
27.5 M | 23 M | 15.2 M | 25.8 M | 26.3 M | 36.6 M | 46.6 M | 22.2 M | 49.3 M | 65.1 M | 108 M | 28.9 M | 28.9 M | 28.9 M | 28.9 M | 39.4 M | 39.4 M | 39.4 M | 39.4 M | 61.3 M | 61.3 M | 61.3 M | 61.3 M | 32 M | 32 M | 32 M | 32 M | 27.8 M | 27.8 M | 27.8 M | 27.8 M | 4.78 M | 4.78 M | 4.78 M | 50 M | 777 K | 14.4 M | 14.4 M | 14.4 M | 145 K | 7.9 M | 7.9 M | 7.9 M | 253 K | - | - | - | 468 K | - | - | - |
Book Value |
-1.6 M | 15.3 M | 35.2 M | 55.3 M | 78.3 M | - | 97.3 M | 72.4 M | 89.5 M | 109 M | 126 M | 95 M | 95 M | 95 M | 95 M | 56.5 M | 56.5 M | 56.5 M | 56.5 M | 66.6 M | 66.6 M | 66.6 M | 66.6 M | 22.5 M | 22.5 M | 22.5 M | 22.5 M | 40.7 M | 40.7 M | 40.7 M | 40.7 M | -5.15 M | -5.15 M | -5.15 M | -5.15 M | 531 K | 89.1 M | 89.1 M | 89.1 M | 21.2 M | 21.2 M | 21.2 M | 21.2 M | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
-1.6 M | 15.3 M | 35.2 M | 55.3 M | 78.3 M | 103 M | 97.3 M | 72.4 M | 89.5 M | 109 M | 126 M | 95 M | 95 M | 95 M | 95 M | 56.5 M | 56.5 M | 56.5 M | 56.5 M | 66.6 M | 66.6 M | 66.6 M | 66.6 M | 22.5 M | 22.5 M | 22.5 M | 22.5 M | 40.7 M | 40.7 M | 40.7 M | 40.7 M | -5.15 M | -5.15 M | -5.15 M | -5.15 M | 531 K | 72.1 M | 72.1 M | 72.1 M | 105 K | -51 M | -51 M | -51 M | 248 K | - | - | - | -71 M | - | - | - |
All numbers in USD currency